Showing 10,981 - 11,000 results of 27,423 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((teer decrease) OR (nn decrease)) ))', query time: 0.87s Refine Results
  1. 10981

    table1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  2. 10982

    image2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  3. 10983

    table2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  4. 10984

    image1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  5. 10985

    table5_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  6. 10986

    table4_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  7. 10987

    Assessing and Responding to Palliative Care Needs in Rural Sub-Saharan Africa: Results from a Model Intervention and Situation Analysis in Malawi by Michael E. Herce (644037)

    Published 2014
    “…</p><p>Conclusions</p><p>We identified a high prevalence of pain and psychosocial needs among patients with serious chronic illnesses in rural Malawi. …”
  8. 10988
  9. 10989

    Image2_Tourniquet application in primary total knee arthroplasty for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.tif by Jinchang Han (14335419)

    Published 2023
    “…</p>Methods<p>Two authors independently retrieved PubMed, Embase, and CENTRAL to identify eligible randomized controlled trials (RCTs) evaluating the effectiveness of a tourniquet in TKA. Fixed- (I<sup>2 </sup>< 50%) or random-effects (I<sup>2 </sup>> 50%) models were selected to perform meta-analysis according to the value of I<sup>2</sup>. …”
  10. 10990

    Table1_Tourniquet application in primary total knee arthroplasty for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.doc by Jinchang Han (14335419)

    Published 2023
    “…</p>Methods<p>Two authors independently retrieved PubMed, Embase, and CENTRAL to identify eligible randomized controlled trials (RCTs) evaluating the effectiveness of a tourniquet in TKA. Fixed- (I<sup>2 </sup>< 50%) or random-effects (I<sup>2 </sup>> 50%) models were selected to perform meta-analysis according to the value of I<sup>2</sup>. …”
  11. 10991

    Image1_Tourniquet application in primary total knee arthroplasty for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.tif by Jinchang Han (14335419)

    Published 2023
    “…</p>Methods<p>Two authors independently retrieved PubMed, Embase, and CENTRAL to identify eligible randomized controlled trials (RCTs) evaluating the effectiveness of a tourniquet in TKA. Fixed- (I<sup>2 </sup>< 50%) or random-effects (I<sup>2 </sup>> 50%) models were selected to perform meta-analysis according to the value of I<sup>2</sup>. …”
  12. 10992
  13. 10993
  14. 10994
  15. 10995
  16. 10996
  17. 10997
  18. 10998

    DataSheet_1_Close association between lifestyle and circulating FGF21 levels: A systematic review and meta-analysis.docx by Zonghao Qian (11334096)

    Published 2022
    “…Overall, smoking, a hypercaloric carbohydrate-rich diet, a hypercaloric fat-rich diet, amino acid or protein restriction, excessive fructose intake and alcohol consumption significantly upregulated cFGF21 levels (p<0.05), whereas fish oil intake and calorie restriction with sufficient protein intake significantly decreased cFGF21 (p<0.05). …”
  19. 10999

    Table 1_Association of lifestyle factors with mortality risk in people with chronic obstructive pulmonary disease: a prospective cohort study.docx by Yue Zhang (30585)

    Published 2025
    “…During a median follow-up of 5.8 years, compared with patients with low LE8 scores, those with moderate and high score presented decreased all-cause mortality (both log-rank p < 0.05) and increased 10-year survival rates (63.6, 72.4 and 89.9%, respectively). …”
  20. 11000